TECH — BIO-TECHNE CORP
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying TECH?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 3 tracked investors who changed their TECH position last quarter, 3 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime). 0 congressional purchases, 1 sale disclosed in the last 6 months.
- +3 tracked investors added or increased positions last quarter (Ken Griffin, Steve Cohen, Ray Dalio)
- +5 tracked investors reported holding TECH at their latest filing
- −Congressional disclosures lean toward selling (1 sales vs 0 purchases, 6 months)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.
About BIO-TECHNE CORP (TECH)
BIO-TECHNE CORP (TECH) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $58M. Across recent filings, tracked investors recorded 7 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in TECH
How many top investors track TECH
A small number of top investors own this.
TECH Ownership Composition
How BIO-TECHNE CORP is held across tracked investor types, based on reported 13F positions.
- Other73.4%
- Hedge Funds26.6%
Tracked investors reporting TECH
- Ken GriffinMar 31, 2026Citadel AdvisorsShares174.2KValue$9.1M% Portfolio0.00%
- Paul Tudor JonesDec 31, 2025Tudor Investment CorpShares518.1KValue$30.5M% Portfolio0.06%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares295KValue$15.4M% Portfolio0.02%
- Izzy EnglanderDec 31, 2025Millennium ManagementShares45.5KValue$2.7M% Portfolio0.00%
- Ray DalioMar 31, 2026Bridgewater AssociatesShares6KValue$312.4K% Portfolio0.00%
Recent activity
- $30.5MFeb 17, 2026
- $2.7MFeb 17, 2026
- New$9.1MMay 15, 2026
- New$15.4MMay 15, 2026
- New$312.4KMay 15, 2026
- Sold$0(-100.00%)Feb 13, 2026
- New$19MNov 14, 2025
- New$2.3MNov 13, 2025
Frequently asked questions
- How many institutional investors hold TECH?
- 5 tracked institutional investors disclosed a position in TECH (BIO-TECHNE CORP) in their most recent 13F filing.
- Who is the largest institutional holder of TECH?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in TECH, valued at $58M.
- Did institutional ownership of TECH increase or decrease?
- Across recent 13F filings, tracked investors recorded 7 new positions, 0 increased, 0 reduced, and 1 fully exited TECH.
- Where does this TECH ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.